Literature DB >> 27338901

Denosumab: a case of MRONJ with resolution.

C V Lyttle1, H Patterson2.   

Abstract

A patient was referred by a clinical oncologist regarding a non-healing area of bone in the lower jaw. The patient was taking denosumab (Prolia(®), Xgeva(®)) when they had a tooth extracted and the area failed to heal. Following suspension of the drug, the area healed with mucosal coverage. This new class of drugs are being increasingly used as an alternative antiresorptive drug to bisphosphonates and are licenced in the UK for prevention of osteoporotic fractures and prevention of skeletal-related events (SREs) in patients with metastatic cancer.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27338901     DOI： 10.1038/sj.bdj.2016.443

Source DB:  PubMed          Journal:  Br Dent J        ISSN： 0007-0610            Impact factor:   1.626


  7 in total

1.  Denosumab.

Authors:  Eline A Dubois; Robert Rissmann; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 2.  Infection and medication-related osteonecrosis of the jaw.

Authors:  H Katsarelis; N P Shah; D K Dhariwal; M Pazianas
Journal:  J Dent Res       Date:  2015-02-20       Impact factor: 6.116

3.  Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?.

Authors:  Harlene Kaur Sidhu
Journal:  Dent Update       Date:  2015-06

4.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

Review 5.  A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.

Authors:  Michael Pazianas; Paul Miller; William A Blumentals; Myriam Bernal; Prajesh Kothawala
Journal:  Clin Ther       Date:  2007-08       Impact factor: 3.393

Review 6.  Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

Authors:  Matthias Troeltzsch; Timothy Woodlock; Stefanie Kriegelstein; Timm Steiner; Karl Messlinger; Markus Troeltzsch
Journal:  J Can Dent Assoc       Date:  2012       Impact factor: 1.316

Review 7.  Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.

Authors:  Stefano Sivolella; Franco Lumachi; Edoardo Stellini; Lorenzo Favero
Journal:  Anticancer Res       Date:  2013-05       Impact factor: 2.480
  7 in total
  1 in total

1.  Corrigendum.

Authors: 
Journal:  Br Dent J       Date:  2016-08-12       Impact factor: 1.626
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.